---
title: "Replimune Group Inc reports results for the quarter ended December 31 - Earnings Summary"
date: "2025-02-12 21:39:07"
summary: "Replimune Group Inc reported a quarterly adjusted loss of 79 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -77 cents. The mean expectation of seven analysts for the quarter was for a loss of 67 cents..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Replimune Group Inc reported a quarterly adjusted loss of 79 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -77 cents. The mean expectation of seven analysts for the quarter was for a loss of 67 cents per share. Wall Street expected results to range from -73 cents to -59 cents per share.
* Reported revenue was zero​; analysts expected zero.
* Replimune Group Inc's reported EPS for the quarter was a loss of 79 cents​.
* The company reported a quarterly loss of $66.34 million.
* Replimune Group Inc shares had risen by 6.1% this quarter.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 10.3% in the last three months.​
* In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Replimune Group Inc is $18.00

This summary was machine generated from LSEG data February 12 at 01:39 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact [RefinitivNewsSupport@thomsonreuters.com](http://mailto:RefinitivNewsSupport@thomsonreuters.com))

| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| --- | --- | --- | --- |
| Dec. 31 2024 | -0.67 | -0.79 | Missed |
| Sep. 30 2024 | -0.77 | -0.68 | Beat |
| Jun. 30 2024 | -0.85 | -0.78 | Beat |
| Mar. 31 2024 | -0.79 | -0.82 | Missed |

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3P31EG:0-replimune-group-inc-reports-results-for-the-quarter-ended-december-31-earnings-summary/)
